SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IS SIGNIFICANTLY IMPROVING: A POPULATION-BASED STUDY FROM SOUTHERN SWITZERLAND.

Andrea Bordoni1; Andreas Cerny2; Florian Bihi3; Simona Peverelli1; Paola Mazzola1; Mario Alerci4; Gianluigi Marini5; Luca Mazzucchelli1; Pietro Majno6; and Alessandra Spitale1

1 Ticino Cancer Registry, Institute of Pathology, CH-6600 Locarno, Switzerland. 
2 Center for Liver Diseases, Clinica Luganese SA, CH-6900 Lugano, Switzerland 
3 Hepatology Unit, San Giovanni Hospital, CH-6500 Bellinzona, Switzerland 
4 Radiology Dept., San Giovanni Hospital, CH-6500 Bellinzona, Switzerland 
5 Oncology Dept., Clinica S.Anna, CH-6924 Lugano-Soregno, Switzerland 
6 Surgery Dept., University Hospital Geneva, CH-1210 Geneva, Switzerland

Introduction
During the last 20 years relevant diagnostic procedures and advanced treatments were progressively introduced in the management of hepatocellular carcinoma (HCC).

Objectives
Aim of this study is to assess up-to-date survival trends for HCC in southern Switzerland, a region with the highest incidence in Switzerland.

Materials and Methods
HCC diagnosed in 1996-2009 were selected by Ticino Cancer Registry. Cancer-specific survival (CSS) was performed through the Kaplan-Meier method according to the calendar period of observation: 1996-2000, 2001-2005, 2006-2009. Log-rank test was used to detect differences in survival curves. Simultaneous assessment of prognostic factors was performed by the multivariate analysis of the Cox proportional-hazards regression model.

Results
A total of 619 HCC were analyzed. There was a significant increase of patients undergoing transarterial chemoembolisation (TACE), whereas patients undergoing curative and palliative supportive treatments remained unchanged (p<0.0001). No shift to earlier stages was detected. Significant differences in survival were observed according to age group (p<0.0001), period of diagnosis (p<0.0001), diagnosis technique (p=0.0035), Barcelona-Clinic liver cancer stage (p<0.0001) and treatment approach (p<0.0001). The multivariate analysis confirmed the independent impact on CSS of factors above mentioned, with the exception of the diagnosis technique. Death risk was higher for patients diagnosed in 1996-2000 (HR:1.32;95%CI:1.03;1.68) and 2001-2005 (HR:1.33;95%CI:1.05;1.67) in comparison with 2006-2009 (reference group).

Discussion and Conclusions
The current population-based report describes a major increase in HCC survival. Simultaneously an increased use of TACE has been detected, probable cofactor of the observed survival increase. Possibly, additional efforts could be made to decrease the HCC stage at diagnosis through active surveillance of cirrhotic patients to allow an increase in curative treatments. For sure, efforts should be made to comply with a standardised staging system for HCC, particularly for comparative population-based issues.

Corresponding Author:
Dr. Andrea Bordoni
Ticino Cancer Registry
Institute of Pathology
Via in Selva, 24, CH-6600 Locarno, Switzerland
Tel: +41-91-8160823. Fax: +41-91-8160829
E-mail: andrea.bordoni@ti.ch